Skip to main content
Clinical Trials/NCT00587678
NCT00587678
Completed
Not Applicable

Comprehensive Magnetic Resonance of Peripheral Arterial Disease

University of Virginia1 site in 1 country85 target enrollmentJanuary 2006

Overview

Phase
Not Applicable
Intervention
Simvastatin/Ezetimibe
Conditions
Peripheral Artery Disease
Sponsor
University of Virginia
Enrollment
85
Locations
1
Primary Endpoint
Plaque Volume
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

The purpose of this study is to develop new ways of imaging fatty blockages in the leg arteries to improve upon techniques used now and to develop new ways of understanding how new treatments may affect the disease.

Registry
clinicaltrials.gov
Start Date
January 2006
End Date
October 2009
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Christopher M. Kramer MD

Professor of Radiology and Medicine

University of Virginia

Eligibility Criteria

Inclusion Criteria

  • Patients age 30-85 referred to the vascular imaging laboratory with documented evidence of peripheral arterial disease (0.4\<ABI\<0.9) 96 Normal healthy subjects ages 30-85

Exclusion Criteria

  • Age\<30, \>85
  • GFR less than 45mL/min based on a serum creatinine drawn within 90 days of the MRI:
  • Pregnancy Contraindications to a magnetic resonance examination
  • Intracranial clips
  • Implantable pacemaker and defibrillator
  • Cochlear or intraocular implants
  • Claustrophobia
  • Any metallic implant not listed as magnetic resonance compatible in Shellock F.G ---Pocket Guide to Magnetic Resonance Procedures and Metallic Objects, Update
  • Lippincott, Williams and Wilkins

Arms & Interventions

Randomized

Patients are imaged at baseline and randomized to Simvistatin 40 mg each night or Simvistatin 40mg/Zetia 10mg each night for 2 years

Intervention: Simvastatin/Ezetimibe

Randomized

Patients are imaged at baseline and randomized to Simvistatin 40 mg each night or Simvistatin 40mg/Zetia 10mg each night for 2 years

Intervention: Simvastatin

Ezetemibe

Patients are imaged at baseline and treated with ezetimibe 10mg each night for 2 years.

Intervention: Ezetimibe

Outcomes

Primary Outcomes

Plaque Volume

Time Frame: 2 years

SFA plaque volume

Perfusion Index

Time Frame: 2 years

Perfusion index is a MRI measure of calf muscle perfusion indexed to the arterial input. The value is between 0 and 1 with 0 being worst and 1 being best.

Phosphocreatine Recovery Time Constant - the Time it Takes for Phosphocreatine Levels to Recover to Plateau.

Time Frame: 2 years

Phosphocreatine recovery time constant is the time it takes for phosphocreatine levels to recover to plateau after the completion of exercise. This ranges from 20 to 1000 seconds. 20-40 seconds is normal and any value over 40 seconds is abnormal.

Secondary Outcomes

  • V02 - Maximal Oxygen Consumption(2 years)
  • Low Density Lipoprotein Cholesterol(2 years)
  • Total Cholesterol(2 years)
  • High Density Lipoprotein Cholesterol(2 years)
  • Triglycerides(2 years)
  • Magnetic Resonance Angiographic Index(2 years)
  • Log Treadmill Exercise Time(2 years)
  • 6-minute Walk Distance(2 years)

Study Sites (1)

Loading locations...

Similar Trials